Mehdi Nemati

[ 1 ] - Evaluation of COVID-19 incidence in psoriatic patients receiving Adalimumab

Background: Adalimumab is a highly human monoclonal antibody that binds to tumor necrosis factor, a key proinflammatory cytokine pathogenic in psoriasis. It considers an influential factor in controlling moderate to severe psoriasis. This study aimed to evaluate the impact of Adalimumab on COVID-19 incidence in patients with psoriasis. Methods: This cross-sectional study was performed at Baqiy...